Severe Asthma Treatment Market Overview, Analysis and Forecast 2023 to 2033

Posted by Ganesh Shinde on April 6th, 2023

According to Future Market Insights, the global severe asthma treatment market is predicted to develop at a CAGR of 5.1% from 2023 to 2033. By 2033, the global market for severe asthma therapy is estimated to reach a value of US$ 36.18 billion. The discovery of biologics and other targeted medicines has transformed the treatment of severe asthma, offering hope and respite to millions of individuals throughout the world who suffer from the disease.

The introduction of biologic drugs is one of the most promising advancements in the treatment of severe asthma. Biologics are medications derived from living organisms that can be utilised to target specific immune system pathways that induce inflammation in the airways. In clinical trials, these drugs shown great efficacy and are increasingly being used to treat persons with severe asthma who do not react well to conventional therapy.

Some of the most commonly used biologics for severe asthma treatment include omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. These medications are administered via subcutaneous injections or intravenous infusion and have been shown to reduce asthma exacerbations, improve lung function, and enhance overall quality of life in people with severe asthma.

Overall, the global severe asthma treatment market is expected to continue to grow in the coming years, as more people are diagnosed with severe asthma and new and innovative treatments become available.

Competitive Landscape

Key players in the severe asthma treatment market are Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron Pharmaceutical, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion

Get More Insights@ https://www.futuremarketinsights.com/reports/severe-asthma-treatment-market

Key Segments Profiled in the Severe Asthma Treatment Industry Survey

Drug Class:

• Reslizumab
• Benralizumab
• Anti-inflammatory

Route of Administration:

• Oral
• Inhaled
• Intravenous
• Subcutaneous

Device Type:

• Dry powder inhalers
• Metered dose inhalers
• Soft mist inhalers